Expense and benefit of neoadjuvant treatment in squamous cell carcinoma of the esophagus

BACKGROUND: The effectiveness of neoadjuvant treatment (NT) prior to resection of squamous cell carcinoma of the esophagus (SCCE) in terms of prolonged survival has not been proven by randomized trials. Facing considerable financial expenses and with concerns regarding the consumption of the patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Heise, Joachim W, Heep, Hansjörg, Frieling, Thomas, Sarbia, Mario, Hartmann, Karl A, Röher, Hans-Dietrich
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2001
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC61000/
https://www.ncbi.nlm.nih.gov/pubmed/11737874
http://dx.doi.org/10.1186/1471-2407-1-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC61000/
https://www.ncbi.nlm.nih.gov/pubmed/11737874
http://dx.doi.org/10.1186/1471-2407-1-20

Ejemplares similares